| |
著者: Yu Sawada, Ryosuke Hino, Kayo Hama, Shun Ohmori, Haruna Fueki, Shigenori Yamada, Shoko Fukamachi, Makiko Tajiri, Rieko Kubo, Manabu Yoshioka, Daiki Nakashima, Kazunari Sugita, Ryutaro Yoshiki, Takatoshi Shimauchi, Tomoko Mori, Kunio Izu, Miwa Kobayashi, Motonobu Nakamura, Yoshiki Tokura
雑誌名: Blood. 2011 Apr 14;117(15):3961-7. doi: 10.1182/blood-2010-11-316794. Epub 2011 Feb 16.
Abstract/Text
Cutaneous involvement is seen in ~ 50% of adult T-cell leukemia/lymphoma (ATLL) patients. We investigated the association between skin eruption type and prognosis in 119 ATLL patients. ATLL eruptions were categorized into patch (6.7%), plaque (26.9%), multipapular (19.3%), nodulotumoral (38.7%), erythrodermic (4.2%), and purpuric (4.2%) types. When the T stage of the tumor-node-metastasis-blood (TNMB) classification of mycosis fungoides/Sézary syndrome was applied to ATLL staging, 16.0% were T1, 17.7% T2, 38.7% T3, and 4.2% T4, and the remaining 23.5% were of the multipapular and purpuric types. For the patch type, the mean survival time (median survival time could not be estimated) was 188.4 months. The median survival times (in months) for the remaining types were as follows: plaque, 114.9; multipapular, 17.3; nodulotumoral, 17.3; erythrodermic, 3.0; and purpuric, 4.4. Kaplan-Meier curves of overall survival showed that the erythrodermic type had the poorest prognosis, followed by the nodulotumoral and multipapular types. The patch and plaque types were associated with better survival rates. Multivariate analysis demonstrated that the hazard ratios of the erythrodermic and nodulotumoral types were significantly higher than that of the patch type, and that the eruption type is an independent prognostic factor for ATLL. The overall survival was worse as the T stage became more advanced: the multipapular type and T2 were comparable, and the purpuric type had a significantly poorer prognosis than T1.
PMID 21325600 Blood. 2011 Apr 14;117(15):3961-7. doi: 10.1182/blood-2010-11-316794. Epub 2011 Feb 16.
|
